Much like Nifty companies, pharma giants are now facing a slowdown in earnings growth. After enjoying a joyride through FY24, posting record revenues quarter after quarter, several pharma companies ...

Boehringer’s lung drug Spiriva, approved for chronic obstructive pulmonary disease (COPD) and asthma, generated net sales of 2.4 billion euros, down 11.4% compared with last year, which the ...

The Indian pharmaceutical sector faces mixed growth with a 12% YoY and 5% QoQ rise while IPM growth is projected at 8%.

The firm stated that the stock is already pricing the one-off benefits of its blockbuster respiratory drug Spiriva in FY25 and FY26. Aside from that, the brokerage also remarked that ...

But sales of Spiriva, approved in chronic obstructive pulmonary disease and asthma, have declined by almost 15% although it is still BI’s biggest drug, generating sales of around 3 billion euros.

This reduces the amount of drug deposited on your cheeks ... like Seebri Respimat and Spiriva Respimat. Asthma inhaler differ ...

Lupin's domestic business should see mid- to high-single-digit growth, supported by a steady contribution from generic Spiriva and new launches like gProlensa and gOracea in the US YoY, revenue is ...

They are also used as add-on therapy for asthma maintenance in the case of Spiriva. There is also a combination inhaler called Combivent that contains albuterol, a SABA, and the anticholinergic drug ...